Windlas Biotech Limited Total Liabilities

Latest as of September 2025: Rs2.80 Billion INR ≈ $30.29 Million USD

Windlas Biotech Limited total liabilities. Based on the latest financial reports, Windlas Biotech Limited (WINDLAS) has total liabilities worth Rs2.80 Billion INR (≈ $30.29 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check WINDLAS asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Windlas Biotech Limited (2018–2025)

Total liabilities of Windlas Biotech Limited from 2018 to 2025. This chart illustrates how Windlas Biotech Limited's total liabilities have evolved over time, based on quarterly financial data.

Windlas Biotech Limited Competitors by Total Liabilities

The table below lists competitors of Windlas Biotech Limited ranked by their total liabilities.

Company	Country	Total Liabilities
TCI Express Limited NSE:TCIEXP	India	Rs2.06 Billion
Quang Viet Enterprise Co Ltd TW:4438	Taiwan	NT$8.73 Billion
A Paradise Acquisition Corp. NASDAQ:APAD	USA	$8.47 Million
Brogent Technologies TWO:5263	Taiwan	NT$2.66 Billion
Elanders AB (publ) ST:ELAN-B	Sweden	Skr12.09 Billion
Kolibri Global Energy Inc. Common stock NASDAQ:KGEI	USA	$85.05 Million
GTM Holdings Corp TW:1437	Taiwan	NT$5.53 Billion
Iberpapel Gestion SA MC:IBG	Spain	€65.38 Million

Liability Composition Analysis (2018–2025)

This chart breaks down Windlas Biotech Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see WINDLAS current and non-current assets.

Liquidity & Leverage Metrics

Windlas Biotech Limited Total Liabilities Ratios Explained

Windlas Biotech Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	2.06	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.52	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.34	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Windlas Biotech Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Windlas Biotech Limited (2018–2025)

The table below shows the annual total liabilities of Windlas Biotech Limited from 2018 to 2025.

Year	Total Liabilities	Change
2025-03-31	Rs2.55 Billion ≈ $27.54 Million	+44.48%
2024-03-31	Rs1.76 Billion ≈ $19.06 Million	+39.12%
2023-03-31	Rs1.27 Billion ≈ $13.70 Million	+31.66%
2022-03-31	Rs962.33 Million ≈ $10.41 Million	-0.79%
2021-03-31	Rs970.04 Million ≈ $10.49 Million	-24.70%
2020-03-31	Rs1.29 Billion ≈ $13.93 Million	+23.17%
2019-03-31	Rs1.05 Billion ≈ $11.31 Million	-36.55%
2018-03-31	Rs1.65 Billion ≈ $17.83 Million	--

About Windlas Biotech Limited

NSE:WINDLAS India Drug Manufacturers - Specialty & Generic

Market Cap

$199.70 Million

Rs18.47 Billion INR

Market Cap Rank

#16356 Global

#835 in India

Share Price

Rs876.10

Change (1 day)

-5.12%

52-Week Range

Rs718.35 - Rs1154.75

All Time High

Rs1154.75